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INTRODUCTION
Brain tumors are among the common neoplasms of humans. Primary 
central nervous tumors are the 6th most common tumors in adults. Patients 
tend  to  concentrate  in  institutions  where  diagnostic  and  the  therapeutic 
services are available. The incidence of brain tumors is around 5-6/1,00,000 
population.  Supratentorial  brain  tumors  constitute  about  80%  of  brain 
tumors  in  adults  and  40%  of  tumors  in  paediatric  population.  Brain 
neoplasms are found in 2% of autopsy series and account for 1% of all the 
hospital admissions.31
Gliomas  are  the  most  common  primary  tumors  of  the  CNS  and 
represent approximately one third of all  the intracranial  tumors in adults. 
The therapeutic management and prognosis in patients with gliomas depend 
on the reliable distinction between low and high grade gliomas.
Diagnosis of brain tumors may be delayed as the initial symptoms and 
signs are vague and non specific.  The symptoms include headache,  focal 
seizures and focal neurological deficits with clinical examination revealing 
raised intracranial tension or focal neurological deficits.
Therefore  the  clinicians  rely  heavily  on  imaging  for  an  early  and 
accurate diagnosis. Both CT and MRI provide excellent anatomical details 
and information regarding the presence, location and extent of brain tumors.
Computed tomography is the baseline imaging modality to evaluate 
patient  with  gliomas.  Although  CT  scan  has  proved  to  be  an  effective 
method  for  the  diagnosing  supratentorial  tumors,  infiltrative  lesions  with 
attenuation similar to normal structure may not be imaged unless they are 
large enough to cause significant mass effect. Superficially situated tumors 
are also often obscured by artifacts caused by calvaria. It is estimated 11.5% 
of hemispheric tumors are not demonstrated by CT.1
               The neurosurgical care and prognosis of patients with cerebral 
gliomas  depend  on  the  accurate  definition  of  tumor  grade.  The  imaging 
characteristics of gliomas are not specific enough to obviate the need for 
biopsy.1
AIM OF THE STUDY
1. To  study  the  distribution  of  various  subtypes  of  gliomas  with 
regard to age, sex and site
2. Histopathological categorization of gliomas and grading them as 
per the WHO 2000 classification of central nervous system tumors.
3. To correlate  the  radiological  findings  with the  histopathological 
grading of gliomas. 
MATERIALS AND METHODS
The study comprised of 110 patients of which 73 were males and 37 
were females ranging from 1 to 65 years. The study was conducted from 
May 2005 to August 2007.
The patients were from Institute of Neurology, Government General 
Hospital, Chennai-3, Institute of child Health, Egmore, Chennai-8 and the 
study was conducted in the Department of Neuropathology, Madras medical 
College, Chennai-3.
Inclusion criteria:
Patients diagnosed to have gliomas by imaging studies and who were 
subsequently operated.
Exclusion criteria:
1. Patients unable to provide informed consent.
2. Women of childbearing potential
3. Patients with significant hepatic or renal dysfunction.
CT  was  done  with  Toshiba  X  SPEED  Third  generation  scanner 
machine.  Axial  study  with  contrast  was  performed  in  all  cases  and  the 
contrast used was 60 ml of Iohexol.
MRI  was  performed  using  1.5  Tesla  superconducting  SIEMENS 
MAGNETOM. T1 WI,  T2 WI and FLAIR sequence  was  done.  Contrast 
study  was  done  in  all  cases  using  0.1mmols/kg  of  Dimeglumine 
Gadopentilate.
The specimens received after the surgery were fixed in 10% buffered 
formalin and manually  processed.  Gross features like size,  shape,  colour, 
consistency,  cystic  and  necrotic  changes  were  noted.  The  tissues  were 
mostly  in  fragments.  Wherever  possible  the  specimens  were  bisected 
longitudinally  and  a  minimum  of  four  bits  each  measuring  3  to  5  mm 
thickness was taken.  After  manual  processing sections of 3 to 5 microns 
thickness were cut and stained with hematoxylin and eosin. 
PROCEDURE FOR HEMATOXYLIN AND EOSIN STAINING36 
1. Dewax  the  section,  dehydrate  through  graded  alcohols  and  bring 
sections to water.
2. Remove fixation pigments if necessary, stain in Harris Hematoxylin 
for 5 minutes.
3. Wash well in running tap water. 
4. Differentiate in 1% acid alcohol for 2- 4 seconds. 
5. Wash well in running tap water until sections are blue again for 15 – 
20 minutes.
6. Stain in eosin for one minute 
7. Wash in water for 5 minutes
8. Dry the sections, clear in xylene, mount with DPX, and label the slide.
      For interpretation and correlation the following aspects of gliomas were 
studied and analysed.
1. Age and sex
2. Site of the tumor
3. CT characteristics:
Density 
Calcification
Mass effect
Contrast enhancement
4. MRI characteristics:
T1 signal intensity
T2 signal intensity
FLAIR
Contrast enhancement
5. Histopathological features
Cellularity
Nuclear pleomorphism
Mitosis
Giant cells
Necrosis
Endothelial proliferation
Calcification
The gliomas were subtyped into various histological grades as per the WHO 
2000  classification  of  Central  Nervous  System  tumors.  Mixed  papillary 
ependymoma,  subependymoma and ependymoma with  spinal  localization 
were  excluded  from  the  analysis  because  these  tumours  if  included 
confounded the results.
REVIEW OF LITERATURE
Gliomas of astrocytic, oligodendroglial and ependymal origin account 
for more than 70% of all brain tumors. 
The most frequent (65%) and most malignant histologic subtype is the 
glioblastoma.  Since  the  introduction  of  computerized  tomography  and 
magnetic resonance imaging, the incidence rates of brain tumors have been 
rather stable.20
The parenchyma of the CNS is composed of primarily of neurons and 
glia.  In  turn  the  glia  is  composed  of  3  types  of  cells,  astrocytes, 
oligodentrocytes  and  ependymal  cells.  While  neoplasms  can  arise  from 
either the neuronal or glial components of the CNS, the glial tumors are by 
far more important both in terms of frequency and clinical aggressiveness.
CLASSIFICATION OF CNS TUMORS
The attempt  to  classify  tumors  of  nervous  system has a  history  of 
nearly 150 years. The initial major classification system was published in 
1926 by Percivial Bailey et al neuropathologist working with neurosurgeon 
Havey Cushing et al.2
            This  classification  divided tumor  types into 14 groups,  with 
medulloepithelioma  arising  from  medullary  epithelium giving  rise  to  all 
other  malignant  neoplasms.  In  this  hierarchical  classification  system, 
medulloepithelioma differentiated  into pineoblastoma,  ependymoblastoma, 
spongioblastoma  multiforme  (glioblastoma  multiforme),medulloblastoma 
and  neuroblastoma.  The  most  differentiated  neoplasms  –  pinealoma, 
ependymoma,  astrocytoma  fibrillae  and  astrocytoma  protoplasmaticum, 
oligodendroglioma and ganglioglioma and choroids plexus papilloma were 
at  the  base  chart  with  choroid  plexus  papilloma  arising  directly  from 
medulloepithelioma. Bailey and Cushing et al.3 also established an expected 
clinical outcome for each tumor type in their classification scheme.
Oligodendroglioma was initially considered a differentiated form of 
medulloblastoma. The classification system was simplified in the next few 
years when Bailey and Bucy et al4 using the histological staining technique 
developed by del Rio Horteja,  proved the presence of oligodendrocytes in 
oligodendrogliomas  and  reclassified  these  tumors  of  glial  cell  lineage. 
Bailey  et  al made further  changes,  combining the two astrocytic  tumors, 
eliminating  the categories  of  medulloepithelioma,  ependymoblastoma  and 
neuroblastoma,  noting  that  choriod  plexus  papilloma  was  not  usually 
considered a glioma. 
Kernohan  &  Sayre  et  al26 classified  tumors  into  5  subtypes  – 
astrocytoma,  oligodendroglioma,  ependymoma,  gangliocytoma  & 
medulloblastoma and more importantly added a grading system. Russell and 
Rubinstein et al38 considered Kernohan’s system oversimplified because of 
omission of certain rare but real tumors such as neuroepilthelioma and polar 
spondioblastoma.  They  also  believed  tumors  should  be  graded  based  on 
postmortem examination, when large sample could be analysed.
Under the auspices of the WHO, neuropathologists met twice in the 
1970’s  and developed a  new classification  and grading system for  brain 
tumors, which Zulch et al published in 1979.53 The classification system was 
to be comprehensive, clarify existing controversies in tumor typing, provide 
a histological grading system across a variety of intracranial neoplasms and 
provide  a  means  of  communication  between  neuropathologists, 
neurosurgeons,  neuro-oncologists,  radiation  oncologists  and  other  health 
professionals  involved in the treatment of brain tumors.  Kleihuer,  Burger 
and Scheithauer et  al27 after  two international working group meetings in 
1988 and 1990 revised the system in 1993.
The  introduction  of  the  second  edition  of  the  WHO classification 
system  takes  the  compromise  position  that  grading  is  not  necessary  for 
tumor typing but if a grading system is used it should be identified.
The  current  international  histological  classification  of  CNS tumors 
drafted in 2000 revision by the WHO has been adapted and modified from 
Kleihuer P Caverer W.K et al .32
WHO CLASSIFICATION OF GLIOMAS 53   
ASTROCYTIC TUMORS               ICD-O CODE
Diffuse astrocytomas 9400/3
Fibrillary astrocytomas 9420/3
Protoplasmic astrocytomas 9410/3
Gemistocytic astrocytomas 9401/3
Glioblastoma 9440/3
Giant cell Glioblastoma 9441/3
Gliosarcoma 9442/3
Pilocytic astrocytomas 9421/1
Pleomorphic xantho astrocytomas 9424/3
Subependymal giant cell astrocytomas 9384/1
OLIGODENDROGLIAL TUMORS
Oligodendroglioma 9450/3
Anaplastic Oligodendroglioma 9451/3
MIXED GLIOMAS
Oligoastrocytomas 9382/3
Anaplastic Oligoastrocytomas 9382/3
EPENDYMAL TUMORS
Ependymoma 9391/3
Cellular Ependymoma 9391/3
Papillary Ependymoma 9393/3
Clear cell Ependymoma 9391/3
Tanycytic Ependymoma 9391/3
Anaplastic Ependymoma 9392/3
Myxopapillary Ependymoma 9394/1
Subependymoma 9383/1
ASTROCYTOMA
Astrocytoma  is  the  most  common  primary  CNS  tumor.  The  term 
astrocytoma was used as early as the late 19th century by Virchow et al but 
was firmly introduced and histopathologically classified in 1926 by Bailey 
and cushing et al.
Many  grading  systems  have  been  frequently  used  in  describing 
astrocytomas.  The kernohan system introduced in 1950 by Kernohan and 
Sayre  et  al26 divided  astrocytomas  into  grade  I  to  IV  with  increasing 
malignancy. Grade III and IV astrocytomas were called glioblastomas and 
both  contained  mitosis,  endothelial  proliferation  and  necrosis.  A  sharp 
distinction did not exist between them using these grades. 
In  1950,  Ringertz  et  al  35 developed  a  three  tiered  system  of 
astrocytoma,  anaplastic  astrocytoma  and  glioblastoma  multiforme  using 
increasing  vascular  proliferation  and  necrosis  as  criteria  for  increasing 
malignancy.
In 1979, the first WHO classification was developed by Zulch et al.53 
To  develop  a  reproducible  grading  system,  Doumas  Duport  et  al  and 
colleagues  proposed  a  discrete  grading system based  on  the  presence  or 
absence of nuclear atypia, mitosis, endothelial proliferation and necrosis in 
pathological specimen and termed it as St Anne/Mayo system. If no criteria 
is present the tumor is classified as grade I, if one criteria, grade II, if two 
criteria, Grade III and if 3 or 4 criteria are present then its grade IV.  
Glioblastoma was identified  by  Virchow in 1863 as being of  glial 
origin, but it took several decades by Strauss and Globus et al46 to give the 
first  comprehensive  description  of  this  tumor.  A  detailed  histological 
account  was  given  by  Zulch53,  Russell  and  Rubinstein  et  al.38 In  the  1st 
edition of WHO classification of tumors of CNS glioblastoma was grouped 
with the medulloblastoma in the category termed poorly differentiated and 
embryonal  tumors.  It  was  probably  the  introduction  of  GFAP 
immunohistochemistry that finally confirmed its origin from differentiated 
astrocytes.  Scherer  et  al40 in  1940  first  introduced  the  term primary  and 
secondary glioblastomas.
A  COMPARISION  OF  PATHOLOGIC  GRADING  SYSTEM 
COMMONLY USED IN ASTROCYTOMAS18.
Kernohan
Ringertz 
1950
WHO 
1979
UCSF 1989
Mayo/
St.Anne 
1993
WHO
1993
WHO
2000
Grade I
Mildly 
anaplastic
Grade I
Pilocytic 
astrocytoma
Grade II Astrocytoma - do -
Mildly 
anaplastic
Grade II
Astrocytoma 
or anaplastic 
astro
Diffuse 
astrocytoma
Grade III
Anaplastic 
astrocytoma
- do -
Moderately 
anaplastic
Grade 
III
GBM
Anaplastic 
astrocytoma
Grade IV GBM GBM GBM
Grade 
IV
GBM GBM
Pilocytic  astrocytoma  was  initially  discussed  in  1918  by  Ribbert. 
Bailey and Cushing et al3included it in their initial brain tumor classification 
in 1926, under the name spongioblastoma.
In  1931,  Penfield  et  al33 called  these  tumors  piloid astrocytoma to 
describe the elongated bipolar and multipolar cells.
Kagan and Rubinstein et all38 named the same tumor astrocytoma of 
juvenile  type  because  of  the  age  group  in  which  it  occurred  and  to 
differentiate it from the more malignant glial neoplasms. The 2000 WHO 
classification system groups all piloid tumors with the biphasic pattern as 
pilocytic astrocytoma.
Kepes et al24 described a relatively rare but well recognized variant of 
cerebral astrocytoma and called it Pleomorphic Xanthoastrocytoma.
OLIGODENDROGLIOMA
In  general  most  of  the  grading  schemes  divide  oligodendroglial 
tumors  into  low  grade  and  high  grade  lesions  (two  -  tier  systems). 
Accordingly,  the  WHO  distinguishes  two  grades:  WHO  grade  II 
corresponding to oligodendroglioma and oligoastrocytoma and WHO grade 
III  corresponding  to  anaplastic  oligodendroglioma  and  anaplastic 
oligoastrocytoma.
The Smith grading system separates oligodendroglial tumors into four 
groups based on assessment of endothelial  proliferation, necrosis,  nuclear 
cytoplasmic ratio, high cell  density  and pleomorphism - notably omitting 
mitotic activity as a major variable. 
The Kernohan grading scheme and the St.Anne Mayo grading scheme 
can  also  be  applied  to  oligodendrogliomas  and  show  correlation  with 
survival.  
 A two grade scheme as also been proposed by Daumas Deport et al11 
that  incorporates  neuro  imaging  features  as  well  as  histology.  Grade  A 
tumors  are  characterized  by  absence  of  endothelial  hyperplasia  and/or 
contrast enhancement on imaging while grade B tumors are characterized by 
endothelial  hyperplasia  and/or  contrast  enhancement  on  imaging.  Median 
survival for grade A lesion was 11 years while that for grade B lesion was 
3.5 years. The presence of microvascular proliferation was correlated with 
survival in this series while nuclear atypia, necrosis and mitosis were not 
predictive of survival.
Mixed  Oligoastrocytomas  were  first  recognized  as  an  entity  by 
Cooper10 in 1935.
EPENDYMOMA 
Virchow et al  published the first  description of an ependymoma in 
Germany in the 1860’s during the American civil war. In 1924, Bailey et al 
first  classified  ependymomas  as  glial  tumors  and  in  1926,  Bailey  and 
Cushing et al3 developed the histological classification of brain tumors with 
primitive spongioblast as the cell of origin. Ependymomas were the more 
differentiated tumors of this classification.
Kernohan and Fletcher et al26 studied 108 cases of ependymomas and 
classified  the  tumors  according  to  their  histological  types  as  epithelial, 
myxopapillary and cellular.
IMAGING MODALITIES
A  variety  of  imaging  modalities  have  been  evaluated  in  accurate 
identification of glioma grade and clinical characteristics.
Tumor imaging has changed dramatically since 1970. The modern era 
of CNS imaging began in 1973 with introduction of computed tomography 
by Oldendorf and Hounsfield et al.
CT was the first brain imaging method to determine the tumor size. 
Baker et al5,6 reviewed the impact of CT in the diagnosis of brain tumors and 
found  that  it  significantly  altered  the  method  and  timing  of  diagnostic 
evaluation  of  the  patients  with  suspected  brain  tumors.   The  areas  of 
structural  abnormality  eg.,  tumors  appeared  on  CT as  regions  of  altered 
tissue radiographic density.
CT is the baseline imaging modality to evaluate patients with gliomas. 
Newer  multislice  helical  or  spiral  CT scanners  are  capable  of  providing 
highly  collimated  submillimeter  thickness  sectional  images  in  extremely 
short acquisition time and thus intra tumor calcification, early intratumoral 
and  peritumoral  hemorrhage  and  bone  destruction  are  more  completely 
defined with great certainty on CT. CT remains a major imaging technique 
for the follow up study of intra cranial lesion.
The development of magnetic resonance imaging fostered a clinical 
partnership among neurologist, neurosurgeon, neuroradiologist and radiation 
oncologist for the interpretation of the same.
MRI,  the static  imaging  procedure of  choice for  brain tumors  was 
developed  in  the  mid  1980’s.  Damadrin  and  Hindshaw  et  al,  in  1980 
demonstrated  the  multiplanar  facility  of  MRI  and  reported  the  first 
demonstration of intracranial pathology using MRI.
MRI with or without gadolinium is the procedure of choice for the 
initial  diagnostic  imaging of  patients,  suspected  of  having an intracranial 
primary brain neoplasm. Zimmerman and Prince et al34,  51 found that MRI 
was more sensitive compared to CT in lesion identification.
Fluid  attenuation  inversion  recovery  (FLAIR)  scans,  T2  weighted 
MRI  are  the  two  most  useful  scans.  The  margins  of  the  T2  weighted 
abnormality are a more accurate marker of the primary glioma boundary.
Dean et al13 introduced a MRI scoring system based on 7 criteria for 
the non invasive  grading of  astrocytomas.  This  scoring system was later 
modified  by  Asan  et  al  who  incorporated  the  following  9  criteria: 
heterogeneity, cyst formation or necrosis,  hemorrhage, tumor crossing the 
midline, edema and/or mass effect, definition of border, flow void, degree of 
contrast  enhancement.  They  suggested  that  it  may  be  possible  to 
differentiate low grade astrocytoma easily from high grade astrocytoma on 
MRI by using MRI scoring system using the 9 criteria. It was inferred that 5 
out of 9 criteria were significantly lower in low-grade gliomas than in high-
grade gliomas. These criteria were heterogeneity, cyst formation or necrosis, 
edema  and/or  mass  effect,  definition  of  border,  degree  of  contrast 
enhancement. 
R. Ashok Kumar and Niranjan Khendelwal et al1 conducted a study 
and applied MRI scores to both astrocytomas and oligodendrogliomas. The 
data revealed significant difference between the mean MRI scores of low 
grade  (Grade  I-II)  and  high  grade  (grade  III-IV)  yielding  the  maximum 
accuracy with 0.9 as the mean MRI score. By using this threshold, contrast 
enhanced MRI enabled correct identification of tumor grade in 15 patients, 3 
low grade gliomas were graded as high grade gliomas and one high grade 
glioma was graded as low grade glioma. This corresponded to a sensitivity 
of 90%, specificity of 66.66% and overall accuracy of 78.94%.
Thus an effective MRI scoring system for grading can be formulated 
for all gliomas including astrocytomas, oligodendrogliomas and mixed glial 
tumors.
The  current  reference  standard  for  determining  glioma  grade  is 
histopathological assessment according to the Joint Section on Tumors of 
the  American  Association  of  Neurological  Surgeons/Congress  of 
Neurological Surgeons. However the limitations of histopathology obtained 
are well known because
1. Only a few small samples of tissue are assessed particularly from 
stereotactic biopsy, the most malignant portion of the tumor may 
not be sampled (sampling error).
2. It  may  be  difficult  to  obtain a  range of  sample  if  the tumor  is 
inaccessible to the surgeon.
3.  There  are  numerous  classification/grading  systems  between 
different institutions.
4. Interpathologist and intrapathologist variability.
5. The  dynamic  nature  of  CNS  tumor  with  at  least  50% 
dedifferentiating into more malignant grades.
STEREOTACTIC BIOPSY
Surgery for neoplasms within the brain and its surrounding structures 
has evolved over the past 100 years. The advent of the operating microscope 
in the 1970’s and computerized imaging and guidance in the 1990’s have 
provided  significant  technical  advances  in  surgical  technique.  In  1884 
Bennet and Godlee et al7 performed the first successful resection of a brain 
tumor that has been localized by neurological examination and the lesion 
was a low grade tumor.
In  the  mid  1990’s  Spetzegar  U  and  Laborde  G  et  al45 used 
sophisticated  frameless  stereo tactic  devices for  the better  intra  operative 
localization. The operative microscope was brought into clinical use in the 
neurosurgical  operating  room  in  the  1970’s  originally  for  the  vascular 
lesions.  It  has  now  become  standard  operating  tool  for  many  surgical 
approaches to brain tumors.
Franklin Earnest W, Patrick J, Kelly et al16 conducted a study on the 
histopathological  correlation  of  MRI  and  CT  contrast  enhancement  with 
stereo tactic biopsy in six selected patients with brain tumor and inferred that 
regions of contrast enhancement demonstrated by CT and MRI in 4 out of 6 
patients correlated with areas of malignant  neovascularity and endothelial 
proliferation within solid tumor.
The value of intra operative diagnosis of brain tumors was studied by 
Tilgner J, Here M et al.50 A retrospective analysis and regression analysis of 
4589 consecutive stereo tactic biopsies from 5000 patients was analysed and 
was found that  histopathological  diagnosis  is  an important  tool  in neuro-
oncology despite improvement in imaging technique. A high correlation was 
found for WHO type II astrocytomas and with regression analysis for WHO 
type I astrocytomas, glioblastomas and metastasis from this study. 
ETIOLOGY OF GLIOMAS
Analytical epidemiological studies have revealed an increased risk of 
gliomas  in  association  with  a  variety  of  conditions  but  attempts  to 
unequivocally identify a specific causative exposure or environmental agent 
have so far been unsuccessful with the exception of therapeutic irradiation.
There is accumulating evidence that a significant fraction of human 
neoplasms including brain tumors contain DNA sequences identical to SV40 
large T antigen. In astrocytic tumors,  this occurs at a frequency of up to 
50%21. A recent study reported the presence of sequences from SV40 virus 
in  3  of  12 oligodendrogliomas.  More  recently  natural  SV40 strains  have 
been identified in human ependymomas.
Familial clustering of gliomas is not uncommon. The association with 
defined  inherited  tumor  syndromes  includes  the  Li-Fraumani  syndrome, 
Turcot syndrome, Tuberous sclerosis, neurofibromatosis (NF1) and multiple 
enchondromatosis (Maffuci/Ollier’s disease).  
LOW GRADE GLIOMAS
DIFFUSE ASTROCYTOMA (WHO Grade II)
Diffuse  astrocytoma  are  slow  growing,  diffuse,  well  differentiated 
tumors. They arise most commonly in the cerebral hemispheres of young 
adults, aged 20-40 years, but also occur in the pons, medulla and spinal cord 
particularly in children and adolescents.
It constitutes 10% of primary cerebral tumors.  Diffusely infiltrating 
astrocytomas are the most  frequent CNS neoplasm and account for more 
than 60% of all brain tumors.
Low  grade  astrocytomas  typically  affect  young  adults,  while 
glioblastoma  shows  a  peak  incidence  in  the  6th decade.  Anaplastic 
astrocytomas occupy an intermediate  position. Males are most  commonly 
affected.
Because of their infiltrative nature, these tumors usually show blurring 
of the gross anatomic boundaries. There is enlargement and distortion, but 
not destruction of the invading anatomical structures.
Microscopically  three  major  cytological  patterns  are  observed  in 
diffuse astrocytomas.
1. Fibrillary astrocytomas
2. Protoplasmic  astrocytomas
3. Gemistocytic astrocytomas
Fibrillary astrocytoma is the commonest type of histological pattern 
seen in diffuse astrocytomas. Cell density is low to moderate. The cytoplasm 
is  scanty.  Nuclear  atypia  or  irregular  hyperchromatic  nuclei  are  a 
histological  hallmark  distinguishing  normal  and  reactive  astrocytes. 
Microcyst is a characteristic feature (fig 4).
Protoplasmic astrocytoma is a rare variant characterized by neoplastic 
astrocytes showing a small  cell  body with few thin processes with a low 
content of glial filaments.
Gemistocytic astrocytoma in its pure form is an uncommon subtype of 
diffuse  astrocytoma.  Gemistocytes (fig.  6,7)  should amount  to  more  than 
approximately 20% of all  tumor cells.  Gemistocytes are characterized by 
plump,  glassy,  eosinophilic  cell  body  of  angular  shape.  Stout,  randomly 
oriented processes form a coarse fibrillary network. Buger PC, Vogel T et al 
reported the presence  of  perivascular  cuffing.8  This variant  appears  to  be 
particularly prone to progress to anaplastic astrocytoma and glioblastoma.
CT shows an ill defined homogenous hypodense/isodense mass with 
no or very minimal enhancement. Enhancement should raise the suspicion of 
focal malignant degeneration.
In  MRI  T1  weighted  sequence  shows  a  homogenous  hypointense 
mass  with  surrounding edema  rarely.  T2  weighted  sequence  and FLAIR 
show a homogenous hyperintense mass.
PILOCYTIC ASTROCYTOMA (WHO Grade I)
Pilocytic  astrocytoma  is  the  most  common  gliomas  in  children 
represent 10% of cerebral and 85% of cerebellar astrocytomas.
Grossly in the cerebellum, the pilocytic astrocytoma is well delineated 
and appears to expand rather than infiltrate into adjacent brain structures. At 
other sites the border with adjacent structures is less defined. The cut surface 
is  grayish-pink  and  often  shows  mucoid  degeneration  leading  to  the 
formation  of  cysts,  a  hallmark  present  in  more  than  80%  of  cerebellar 
astrocytomas.
Microscopically  two  distinct  varieties  exist,  the  juvenile  form 
described by Russel and Rubenstein et al and the adult variant described by 
Clarke et al. most pilocytic astrocytomas have biphasic histological pattern 
(fig. 1) with areas of pilocytic cells and microcystic areas containing stellate 
cells with defined processes.38 Both types of cells contain glial fibrils. The 
adult variant has monotonous areas of densely packed broad bipolar without 
microcystic  areas.  Rosenthal  fibres  (fig  2),  eosinophilic  granular  bodies 
(fig.3) are often seen.
CT  demonstrates  discrete  cystic/solid  mass  with  little  or  no 
surrounding edema. Mural nodule can be seen within the cysts. More than 
95%  of  them  enhance  with  contrast.  T1  weighted  images  show  iso  to 
hypointense areas while T2 weighted images shows hyperintense areas.
PLEOMORPHIC XANTHOASTROCYTOMA (WHO Grade II)
This accounts for less than 1% of astrocytic tumors. 98% of tumors 
arise above the tentorium with a proclivity for the temporal lobe. 
Grossly cystic and solid components are made out. Cystic spaces may 
be  quite  conspicuous  containing  voluminous  dark  golden,  xanthochromic 
serous  fluid.  The mural  nodule is  of  varying colour,  with a  predominant 
yellow-orange hue. 
The most  striking histopathological  features are multinucleated  and 
lipidized giant cells (fig. 17) with bizarre, often hyperchromatic nuclei. In 
addition, there are small round/polygonal and fusiform cells often arranged 
in fascicular patterns. Tumors with prominent vasculature have been termed 
as angiomatous variant by Sugita Y, Kepes JJ et al.47
CT shows cystic/solid mass which is hypodense with mixed density 
mural  nodules,  the  nodules  shows  strong  enhancement  with  contrast 
(fig.VIIa,b).
T1 weighted image shows hypointense or isointense mass while T2 
weighted image shows hyperintense or mixed signal intensity mass.
OLIGODENDROGLIOMA (WHO Grade II)
The important feature of oligodendroglioma is the dominant presence 
of  cells  which  cytologically  resemble  normal  oligodendrocytes. 
Oligodendrogliomas  represent  less  than  5% of  all  primary  CNS tumors. 
Helseth A, Mork S J et al have found that the incidence of the tumor is 7.9% 
of all gliomas.19 
These tumors arise between the ages 35 to 55 with the peak around 45 
years. Male to female ratio is 1.5 to 2:1 according to Zulch K et al.52Most of 
the oligodendrogliomas arise in the periphery of the cerebral hemispheres in 
the frontal, parietal, temporal, occipital lobes in the ratio of about 3:2:2:1.
Grossly they are typically solid, soft, tan to pink colour tumors. Some 
lesions have a gelatinous texture which has been related to accumulation of 
extracellular  mucopolysaccharides  within  the  tumor15.  Appearance  of  a 
single  expanded  gyrus  is  highly  characteristics  of  oligodendroglioma. 
Calcification is seen macroscopically in about 50% of these tumors.
Microscopically oligodendrogliomas are composed of glial cells with 
uniform rounded or slightly oval shaped nuclei, small amount of cytoplasm 
and small number of cell processes. Perinuclear halo, highly characteristic of 
oligodendroglioma is probably related to autolytic cytoplasmic vacuolations. 
Blood vessels are typically numerous,  thin walled, straight and branching 
segments and small arcs likened to “chicken wire” (fig. 8). Astrocytic cells 
and mini gemistocytes along with calcification are typical of these tumors.
CT  shows  a  mixed  density  mass  with  nodular  or  clumped 
calcifications. Around 50% of these tumors enhance with contrast. 
In MRI T1 weighted images shows a hemispheric mass which is hypo 
to isointense mass with typically heterogeneous. T2 weighted images and 
FLAIR  shows  heterogeneous,  hyperintense  mass  with  occasional  cystic 
changes. Heterogeneity is related to the calcium present in the tumor.  
OLIGOASTROCYTOMA (WHO Grade II)
The estimated incidence of this tumor varies and represents no more 
than 10 to 20% of supratentorial low grade gliomas. In an analysis of 4859 
patients with different histological types of intracranial gliomas registered 
by  the  Norwegian  Cancer  Registry  between  1956  and  1984,  9.2% were 
mixed gliomas.19 Males are affected slightly more frequently than females 
with  the  ratio  of  1.2:1.  The  frontal  lobes  are  most  commonly  affected 
followed by the temporal lobe.
Histologically  the  diagnosis  of  oligoastrocytomas  requires  the 
recognition  of  two  different  glial  components  both  of  which  must  be 
unequivocally  neoplastic.  The  tumors  in  which  a  clear  fibrillary, 
protoplasmic  or  classic  gemistocytic  astroglial  component  is  evident  in 
addition  to  the  oligodendroglial  cells  are  diagnosed  as  oligoastrocytomas 
(fig.  9).  The  presence  of  neumerous  mini  gemistocytes  should  raise  the 
suspicion of oligoastrocytomas and a search for astrocytic component has to 
be made.
Neuroradiologically,  oligoastrocytomas  demonstrate  no  special 
features  that  would  allow  a  reliable  distinction  from  WHO  Grade  II 
oligodendrogliomas.  In  the  series  of  Shaw  et  al  about  half  of  the 
oligoastrocytomas evaluated by CT scan showed contrast enhancement and 
calcifications were demonstrable in 14% of the tumors.42
EPENDYMOMA (WHO Grade II)
Ependymomas account for 3 to 9% of all neuroepithelial tumors. They 
amount to 6 to 12% of all intracranial tumors in children, and to 30% of 
those in children younger than 3 years. In the spinal cord ependymomas are 
the  most  common  neuroepithelial  neoplasms,  comprising  50  to  60%  of 
spinal gliomas.41 Ependymomas may develop in all age groups with a range 
from one month to 81 years. They most commonly develop in the posterior 
fossa and in the spinal cord, followed by the lateral ventricle and the third 
ventricle.
Grossly they are typically reddish grey in colour and form nodular or 
lobulated  mass  with  some  of  them showing  cystic  elements,  necrosis  or 
hemorrhage.
Microscopically  ependymomas  are  well  delineated  moderately 
cellular  gliomas  with  a  monomorphic  nuclear  morphology.  The  key 
histological features are perivascular pseudo-rosette (fig. 10) and ependymal 
rosettes.  True  ependymal  rosettes  are  relatively  uncommon  and are  most 
often encountered in the posterior fossa tumors in younger age group, where 
it  is claim to have a poor prognosis.22 Focal calcification may be present 
especially in those located supratentorially.
In  supratentorial  ependymomas  CT  shows  large  heterogeneous 
periventricular  mass  with  variable  heterogeneous  enhancement  with 
contrast. Calcification is seen in about half of these cases. Both T1 and T2 
weighted images show a heterogeneous,  usually  iso to hypointense mass. 
FLAIR sequences show a sharp interface between the tumor and CSF. Mild 
to moderate, heterogeneous enhancement is seen with contrast studies.
HIGH GRADE GLIOMAS
ANAPLASTIC ASTROCYTOMA (WHO Grade III)
Anaplastic astrocytoma can be defined as a tumor which was initially 
a diffuse astrocytoma but has undergone anaplastic changes. The anaplastic 
change may be focal and is characterized by;
1. Rapid  deterioration in  the  clinical  state  of  a  patient  with a  diffuse 
astrocytoma.
2. Focal  enhancement  on  CT  or  MRI  in  an  otherwise  diffuse  non 
enhancing astrocytoma.
3. On biopsy by the presence of anaplastic cells in an astrocytic tumor 
with  high  nuclear:cytoplasmic  ratio,  increased  mitotic  activity  and 
raised Ki67/MIB-1 proliferation index.
According to Zurich et al the mean age at which anaplastic astrocytomas 
occur is approximately 41 years. Males are frequently affected.
As with diffuse astrocytomas, anaplastic astrocytomas arise mainly in the 
cerebral hemispheres.
Grossly the higher cellularity of the anaplastic astrocytoma produces a 
discernable  tumor mass with a clearer  distinction from surrounding brain 
structures. As in diffuse astrocytoma, there is a tendency to infiltrate without 
frank  tissue  destruction.  This  often  leads  to  a  marked  enlargement  of 
invaded structures.
Microscopic features are those of a diffusely infiltrating astrocytoma with 
increased cellularity, distinct nuclear atypia (fig. 11,12) and marked mitotic 
activity.  The  anaplastic  areas  are  identified  by  the  crowding  together  of 
tumor cell nuclei. Due to the relative lack of cytoplasm, many of the nuclei 
are  rod  shaped  and  hyperchromatic.  On  rare  occasions  small  regions  of 
infarct like necrosis may be found in anaplastic astrocytomas in the absence 
of highly cellular tumor.
According to Burger PC and Vogel et al, the presence of necrosis would 
indicate a diagnosis of glioblastoma.8 CT findings show a low density ill 
defined  mass  and  with  contrast  an  enhancement  often  focal,  patchy  and 
heterogenous.
In MRI, in T1 weighted images mixed isointense to hypointense mass is 
seen.  In T2 weighted images hererogenous hyperintense mass  is  seen.  In 
FLAIR also hererogenous hyperintense mass is seen.
ANAPLASTIC OLIGODENDROGLIOMA (WHO grade III)
The  percentage  of  anaplastic  tumors  among  all  oligodendroglial 
tumors varies between 15 to 20%*. These tumors manifest in adults with a 
slight  male  predominance.  They  share  with  WHO  grade  II 
oligodendrogliomas a preference for the frontal lobe (60% in the Dusseldorf 
series) followed by the temporal lobe (33%).
Grossly  they  are  soft  masses  of  grayish-pink  colour  with  areas  of 
necrosis.  Histologically  a high cell  density,  moderate  pleomorphism with 
anaplastic nuclei, prominent mitotic activity, microvascular proliferation and 
necrosis are seen.
CT shows a heterogeneous pattern, owing to the variable presence of 
necrosis,  cystic degeneration, intra tumoral hemorrhages and calcification. 
Contrast  enhancement  on  CT  and  MRI  is  usual  and  may  be  patchy  or 
homogeneous. Ring enhancement is uncommon and when present heralds a 
poor prognosis.
ANAPLASTIC EPENDYMOMA (WHO Grade III)
It is a type of malignant glioma of ependymal origin with accelerated 
growth and unfavourable clinical outcome, particularly in children. They are 
more  frequent  in  intracranial  ependymomas,  particularly  posterior  fossa. 
These  tumors  exhibit  a  high  mitotic  activity  often  accompanied  by 
microvascular proliferation and pseudo-palisading necrosis.
 The  features  associated  with increased  likelihood of  malignancy in 
ependymomas:22
1. Posterior fossa or large intracerebral tumors in childhood.
2. Epithelial pattern with tubular-rosettes.
3. Significant mitotic rate.
4. Cytological pleomorphism.
5. Vascular endothelial proliferation.
6. Tumor necrosis
7. Diffuse infiltration of adjacent brain tissue.
GLIOBLASTOMA MULTIFORME (WHO Grade IV)
Glioblastoma is the most malignant astrocytic tumor and accounts for 
12-15% of all intracranial tumors.  Glioblastomas frequently develop from 
low grade or anaplastic astrocytomas (secondary glioblastoma), but may also 
arise  denovo  (primary  glioblastoma).  It  may  manifest  at  any  age,  but 
preferentially affects adults, with a peak incidence between 45 and 75 years. 
They  occur  most  often  in  the  subcortical  white  matter  of  the  cerebral 
hemisphere. Glioblastoma of the brain stem are infrequent and often affects 
children, while cerebellum and spinal cord are rare sites for this neoplasm.
Grossly they are poorly delineated, the cut surface showing a variable 
colour  with  peripheral  grayish  tumor  masses  admixed  with  necrosis  and 
hemorrhage. 
Histopathology of glioblastoma is extremely variable. The presence of 
highly  anaplastic  glial  cells,  multinucleated  tumor  giant  cells,  mitotic 
activity,  microvascular  proliferation  and/or  necrosis  is  required  for  the 
diagnosis  of glioblastoma.  Burger PC, kleihuer P et  al  found that  poorly 
differentiated  fusiform,  round  or  pleomorphic  cells  may  be  seen  atleast 
focally.  This  occurs  in  glioblastomas  resulting  from  the  progression  of 
diffuse  Astrocytomas.8 Large  ischemic  necrosis  and  pseudopalisading 
necrosis are hallmark of primary glioblastoma. Del Bigio MR & Harris et al 
have  reported  large  granular  cell  with  granular  PAS  positive  cytoplasm 
occurring scattered within the glioblastomas.14 Kepes JJ, Mark SJ et al have 
reported  adenoid  and  squamous  epithelial  metaplasia  in  glioblastoma,but 
found it to be more frequent in gliosarcoma.24
CT shows an irregular isodense/hypodense mass with marked mass 
effect  and  surrounding  edema.  95%  of  these  tumors  are  strong, 
heterogenous,  irregular  rim-  enhancement.  T1  weighted  image  shows  an 
irregular  hypointense  mass  while  heterogeneous/hyperintense  mass  with 
adjacent tumor infiltration is seen in T2 weighted images.
GIANT CELL GLIOBLASTOMA (WHO Grade IV)
It  is  a  histological  variant  of  glioblastoma with a predominance of 
bizarre,  multinucleated  giant  cells.  This  rare  variant  usually  occurs  in 
younger age group. They are often located subcortically in the temporal and 
parietal lobes.
    
RESULTS AND OBSERVATION
Table – 1: DISTRIBUTION OF THE HISTOLOGICAL VARIANTS OF 
GLIOMAS
S.No Histological type
Number of cases
n = 110
Percentage
(%)
1 Pilocytic astrocytoma 17 15.45%
2 Pleomorphic xanthoastrocytoma 1 0.90%
3 Diffuse astrocytoma 45 40.90%
4 Oligodendroglioma 3 2.72%
5 Mixed glioma 2 1.81%
6 Ependymoma 4 3.63%
7 Anaplastic astrocytoma 12 10.90%
8 Glioblastoma multiforme 26 23.63%
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Table-2: DISTRIBUTION OF GRADES OF GLIOMAS
S.no Grade
No of cases
(n=110)
Percentage
1 I 17 15.46%
2 II 55 50%
3 III 12 10.91%
4 IV 26 23.63%
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Table-3: SEX DISTRIBUTION
            
S.No Tumor No. of cases Male % Female %
1 Pilocytic astrocytoma 17 11 64.70% 6 35.29%
2 Pleomorphic xanthoastrocytoma 1 1 100% - -
3 Diffuse astrocytoma 45 32 71.11% 13 28.88%
4 Oligodendroglioma 3 2 66.66% 1 33.33%
5 Mixed glioma 2 2 100% - -
6 Ependymoma 4 2 50% 2 50%
7 Anaplastic astrocytoma 12 7 58.33% 5 41.66%
8 Glioblastoma 26 16 61.53% 10 38.46%
Table-4: DISTRIBUTION OF GLIOMAS BY LOCATION
S.No Distribution Number of cases Percentage
1 Supratentorial 100 90.91%
 2 Infratentorial 10 9.09%
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Table-5: AGE DISTRIBUTION
S.No Age P.A P.XA D.A ODG M.G EPEN A.A GBM
1 0-10 9 - 1 - - 1 - -
2 11-20 7 1 2 2 - - - 1
3 21-30 - - 17 1 1 1 6 1
4 31-40 - - 14 - - 2 2 3
5 41-50 1 - 7 - 1 - 1 7
6 51-60 - - 4 - - - 2 11
7 61-70 - - - - - - 1 3
PA : Pilocytic Astrocytoma MG : Mixed glioma
PXA : Pleomorphic Xanthoastrocytoma EPEN : Ependymoma
DA : Diffuse Astrocytoma  AA : Anaplastic Astrocytoma
ODG : Oligodendroglioma GBM : Glioblastoma Multiforme
Table-5: CONTRAST ENHANCEMENT OF GLIOMAS
               Table – 6: CONTRAST ENHANCEMENT OF GLIOMAS
Glioma grading
Total no.
Of cases
(n=110)
Nonenhancing Enhancing
No of
cases
Percentage
(%)
No of
cases
Percentage
(%)
Grade I 17 14 82.35 3 17.64
Grade II 55 47 85.45 8 14.54
Grade III 12 4 66.66 8 33.33
Grade IV 26 2 7.69 24 92.30
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Table-7: MRI SIGNAL CHARACTERISTICS OF GLIOMAS
T1W SEQUENCE
Grade
No. of cases
( n=110)
Hypointense Hyperintense Heterointense
Grade I 17 15(14.45%) - 2 (2.55%)
Grade II 55 51(46.75%) - 4(8.25%)
Grade III 12 11(10.20%) - 1 (1.8%)
Grade IV 26 17(22.1%) - 9 (3.9%)
T2W SEQUENCE
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DISCUSSION
In our study of 110 patients 72 cases (65%) were low grade and 38 
cases  (35%)  were  high  grade.  The  most  frequent  glioma  was  diffuse 
astrocytoma seen in 45 cases (41%) followed by glioblastoma seen in 26 
cases  (24%).  There  were  17  cases  of  pilocytic  astrocytoma,  3  cases  of 
oligodendroglioma, 2 cases of mixed glioma, 4 cases of ependymoma and 
12  cases  of  anaplastic  astrocytoma.  One  case  of  pleomorphic 
xanthoastrocytoma was reported.
Grade
No. of cases
( n=110)
Hypointense Hyperintense Heterointense
Grade I 17 - 14(13.6%) 3 (3.4%)
Grade II 55 - 51(44%) 4 (11%)
Grade III 12 - 7(9.6%) 5 (2.4%)
Grade IV 26 - 18(20.8%) 8 (5.2%)
The  anatomic  location  influences  the  prognosis  and  treatment  of 
gliomas.  Majority of cases were supratentorial and they constituted 91 %
( 100 out of 110) of total cases studied. 23% of cases were in frontal lobe, 
40% were in temporal lobe, 11% in parietal lobe, 3% in occipital lobe and 
14% in deeper structures. 10 cases were situated in posterior fossa and all 
turned out to be low grade gliomas. The statistics were comparable with the 
study done by Suri Larjavara et al.48No differences in location were found 
among glioblastoma, diffuse astrocytoma and anaplastic astrocytoma.
The  most  common  presenting  symptoms  were headache  associated 
with nausea and vomiting. 52% of the cases had these symptoms. New onset 
seizures were the second most common symptoms accounting for 20% of all 
the cases.
A history of head injury preceding the occurrence of glioma could be 
elicited  in  3  patients.  There  are  numerous  anecdotal  reports  on  the 
occurrence  of  gliomas  after  a  head  injury  at  the  same  site.  A  causal 
relationship is usually difficult to prove, although an association would be 
biologically  plausible  since  trauma  induces  a  strong  proliferative 
astrogliosis.12
Children in  particular  presented  with seizures  more  often than  any 
other  symptoms.  Other  symptoms  commonly  observed  were  memory 
disturbances, slurring of speech, diplopia, blurring of vision and hemiparesis 
or hemiplegia. These symptoms were observed mostly in the supratentorial 
gliomas. Some patients experienced drowsiness or were even admitted in a 
comatose condition.
There were 11 patients who had a previous history of cranial surgery. 
Two male  patients  who underwent surgery,  followed by radiotherapy for 
low  grade  astrocytomas  presented  with  glioblastoma.  The  remaining  9 
patients turned out to be recurrent low grade astrocytoma.
AGE SPECIFIC INCIDENCE:
In our study of gliomas there was a wide age range with the youngest 
patient being four months of age and the oldest being 75 years old.
Nearly  all  the  pilocytic  astrocytomas  manifested  in  children  and 
adolescent before the age of 20 years. The peak incidence was between 8 
and 15 years in our study.
Diffuse astrocytomas affected mostly young adults with the peak in 
the third decade with 17 cases  contributing to 37.77% of the cases.  The 
maximum age recorded was in a 58 year old man.
Anaplastic  astrocytomas  manifested  between  the  third  and  sixth 
decade with the maximum age recorded as 65 years.
Glioblastoma multiforme showed a peak incidence between 45 and 70 
years  with  16  cases  falling  in  this  group  (61.54%).  This  finding  is 
comparable  with  the  study  conducted  by  University  hospital,  Zurich12 
wherein two thirds (67%) of patients fell into this age group.
Oligodendrogliomas were commonly seen between third and fourth 
decade while ependymomas were reported in children and adults.
Our study showed a gradually increasing age specific incidence from 
first decade onwards. This peaked in the third decade with 27 cases forming 
24.54%. Thereafter the incidence tapered off till the seventh decade which 
showed only 4 cases constituting 3.63%.
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In our  study of  110 cases  of  gliomas there  were 73 males  and 37 
female patients. The sex specific incidence rate for men was 66.36% and for 
women  was  33.63%.  The  male  predominance  was  seen  in  all  gliomas 
irrespective  of  their  age  and  grade.  This  corresponds  to  epidemiological 
reports from University of Zurich where a male: female ratio of 1.4:1 was 
observed.
IMAGING STUDIES
LOW GRADE ASTROCYTOMAS
Pilocytic astrocytoma:
Most  of  the  pilocytic  astrocytomas  were  moderately  defined  and 
hypodense in plain CT (fig IVa). In our study 3 out of 17 cases of pilocytic 
astrocytomas  showed  contrast  enhancement  (fig  IVb).  2  cases  in  the 
cerebellum  showed  mural  nodule  within  cystic  areas.  2  cases  showed 
calcifications. Most of the cases were hypointense in T1W and hyperintense 
in T2W images. Luh GY, Bird CR et al in 1999 showed that typically after 
intravenous administration of contrast agent there was dense homogenous 
enhancement of tumor nodule but not of the other walls of the cyst.30 There 
were 2 cases in which radiologically appeared to be medulloblastoma turned 
out to be pilocytic astrocytoma on HPE. Both the cases were located in the 
cerebellum. One case of oligodendroglioma and one case of ependymoma 
diagnosed by CT and MRI studies turned out to be pilocytic astrocytoma on 
HPE. Hence the sensitivity is 88.23% in diagnosing pilocytic astrocytoma by 
CT and MRI.
Diffuse Astrocytoma:
Most of the cases displayed no mass effect, no calcification and no 
hemorrhage  (fig  Ia).  Majority  were  non-enhancing with  contrast  while  4 
cases showed enhancement (fig Ib). Smirniotopoulus JG et al showed that in 
low  grade  astrocytomas  the  contrast  enhancement  is  usually  absent 
reflecting  a  lack  of  tumor  vascularity,  blood  brain  barrier  breakdown or 
both.43 The above character is also noted in our study. All lesions appeared 
hypointense in T1; most appeared hyperintense in T2 weighted images (fig 
Ic). Out of the 45 cases of diffuse astrocytomas, 42 cases were reported as 
low grade gliomas by imaging studies, one case reported as glioblastoma 
and  another  case  in  which  the  tumor  was  in  posterior  fossa  reported  as 
hemangioblastoma by CT and MRI turned out to be grade II astrocytoma by 
HPE. One case of parasagittal lesion in which the differential diagnosis was 
given  as  meningioma/tuberculoma  ultimately  turned  out  to  be  diffuse 
astrocytoma. Hence the sensitivity in reporting diffuse astrocytoma is 93.3% 
by imaging.
Oligodendroglioma:
In our study all the 3 cases of oligodendrogliomas were hyperdense on 
plain CT (fig VIa) and showed edema. 2 cases in addition to that showed 
calcifications (fig VIb). On MRI the lesions were heterointense in T1WI and 
T2WI due to calcification. The diagnostic accuracy of oligodendrogliomas 
by  imaging  modalities  in  our  study  is  100%.  Among  the  2  cases  of 
oligoastrocytomas  one  case  showed  calcification  and  one  case  enhanced 
with contrast. 
Ependymoma:
Most of ependymomas were mixed to hyperdense on plain CT (fig 
Va) and 2 cases showed contrast enhancement (fig Vb). Calcification was 
seen  in  one  case.  One  case  of  suprasellar  ependymoma  was  reported  as 
craniopharyngioma by CT and MRI. All the four cases of ependymoma were 
hypo to heterointense on T1WI and hyper to heterintense on T2WI.
Anaplastic astrocytoma:
            The anaplastic astrocytomas were ill defined and exhibited moderate 
mass  effect.  In  our  study  8  out  of  12  cases  (66.66%)  of  cases  showed 
contrast enhancement. Calcification and hemorrhage were not seen. In MRI 
(fig II) almost all cases (11 out of 12 cases) were hypointense on T1W and 
heterointense  on T2W images.  One case  which  showed prominent  cystic 
changes in CT, reported as low grade glioma turned out to be anaplastic 
astrocytoma on histopathology.
Glioblastoma multiforme:
             All cases of gliblastoma multiforme (n=26) were ill defined in CT, 
exhibited more mass effect and heterogeneity and more vasogenic edema. 
All  showed  areas  of  necrosis  and  hemorrhage  which  were  clearly 
demonstrable  in  MRI.  Calcification  was  noted  in  2  cases.  Contrast 
enhancement  was  noted  in  24  (92.30%)  out  of  26  cases  (P  <  0.O1)  of 
glioblastoma, which was moderate to intense (fig III).
       Butler  AR,  Horri  SC et  al  ,  in  their  study  showed  that  contrast 
enhancement  of  viable  tumor  including  the  peripheral  rim  and  the 
intratumoral solid portions is nearly universal in glioblastoma.
       In MRI most lesions (17 out of 26 cases) were hypointense on T1W 
images  and  18  cases  hyperintense  on  T2W  images.  Out  of  26  cases  of 
Glioblastoma 24 cases were diagnosed as  glioblastoma and 2 cases  were 
diagnosed as anaplastic astrocytoma by imaging studies. So, the sensitivity 
in diagnosing glioblastoma by imaging studies is 92.30%.
        Patients  with nonenhancing high grade astocytomas tended to be 
younger at presentation. Our results demonstrate that it is important to obtain 
histologic  confirmation  of  the  diagnosis  in  gliomas  regardless  of  the 
presence or absence of contrast enhancement of the tumor on CT, because 
neither of these characteristics correlates with the tumor histology.
HISTOPATHOLOGY AND GRADING OF GLIOMAS       
Our  study  of  110  gliomas  correlating  neuroimaging  and  histology 
helped us to observe certain microscopic features which enabled us to grade 
the tumors. Our study determines the effectiveness and the reproducibility of 
a  previously  published  method  of  grading  gliomas.  The  main 
histopathological parameters of importance are histological type and tumor 
grade.32Various grading systems are applied to the astrocytomas which are 
classified based on the presumed cell  of origin. These are then classified 
according to their degree of malignancy. Widely used grading systems are 
WHO and St.Anne-Mayo. The main histological signs of malignancy in both 
systems  are  nuclear  atypia,  mitotic  activity,  vascular  proliferation  and 
necrosis.  These criteria are interpreted slightly different  in these systems. 
For example a single mitosis is a sign of grade III (Anaplastic) astrocytoma 
in  St.  Anne-Mayo’s  system  but  higher  mitotic  activity  is  a  sign  of 
malignancy in WHO 2000 classification.32
The  WHO  classification  is  more  descriptive  than  St.Anne-Mayo’s 
system, which is based on presence or absence of 4 major criteria.
A  similar  histological  grading  system  was  attempted  with 
oligodendroglioma, but a 4 grade system appears inefficient. Now there are 
2  malignancy  grades  in  the  WHO  classification  based  on  histological 
parameters similar to astrocytomas.
           As shown in Table no-8 features such as cellularity, nuclear atypia, 
mitosis, giant cells, necrosis and endothelial proliferation were considered.
Table-8: CORRELATION OF HISTOLOGICAL FEATURES WITH 
GRADING
S.No Histological Features No of cases
Low grade 
(%)
High grade (%)
1
Cellularity
Mild to moderate
      High
67
43
61 (91.05)
12 (27.90)
06 (08.95)
31 (72.09)
2 Nuclear pleomorphism 59 23 (38.98) 36 (61.01)
3 Mitosis 40 07 (17.50) 33 (82.50)
4 Giant cells 14 - 14(100.00)
5 Necrosis 23 01 (04.34) 22 (95.66)
6 Endothelial proliferation 26 - 26(100.00)
Cell density and pleomorphism:
           Cellularity is very important in distinguishing reactive gliosis from a 
true astrocytoma. The criterion used to distinguish cellularity is the presence 
of inter nuclear space. If the inter nuclear space is less than that of a single 
nuclear  size  it  means  there  is  dense  cellularity.  Moreover  the  nuclear 
morphology regarding the variation in size is also important to differentiate 
neoplasms from gliosis i.e.  Since neoplasm’s are monoclonal a low grade 
glioma is usually monomorphous compared to the pleomorphism exhibited 
by the cells in reactive gliosis. This is applicable only to low grade gliomas.
            Very  little  information  is  available  about  cell  density  and 
pleomorphism as an independent prognostic factor. In our study, low grade 
astrocytomas  showed  mild  to  moderate  cellularity  with  mild  nuclear 
pleomorphism.  All  the  3  cases  of  oligodendrogliomas  showed  mild  to 
moderate cellularity and mild nuclear pleomorphism. Increased cellularity of 
oligodendroglioma is related to a worst prognosis.17
Table-9 FREQUENCY OF HISTOPATHOLOGIC
FEATURES IN HIGH GRADE GLIOMAS
Features
% in high
grade lesions
(n=38)
% in total
(n=110) “P” value
High cellularity
31 (81.57%)
43(39.09%
) <0.01
Nuclear pleomorphism 36(94.73%)
59(53.63%
)
<0.01
Mitosis 33(86.84%)
40(36.36%
)
<0.01
Giant cells 36(94.73%)
14(12.72%
)
<0.01
Necrosis 22(57.89%) 23(20.90% <0.01
)Endothelial proliferation 25(65.78%)
25(22.72%
)
<0.01
 The high grade gliomas (n=38) showed high cellularity (81.75%) and 
moderate  to marked nuclear  pleomorphism (94.73%). This  showed a  “P” 
value of less than 0.01 which is statistically significant (fig.13). 
Mitotic activity:
Presence of mitotic activity is a bad prognostic sign and is valid to all 
tumours. Many authors use only presence and absence of mitosis. Very little 
information about influence of mitotic count in the field upon prognosis may 
be found in references. Sallinen et al researched the number of mitosis in a 
square millimeter and determined that finding more than 3 mitosis/sq mm 
has  a  statistically  worse  prognosis  than  fewer  mitosis38.  Other  authors 
suggest  that  counting  mitosis  is  an  unreliable  method  for  it  depends 
considerably  upon  tissue  fixation,  processing  and  upon  skills  of  the 
pathologist.
           In our study mitosis was noted in 40 cases (n=110). Among the 40 
cases 33 cases (82.5%) turned out to be high grade gliomas and all of them 
showed a mitotic count >3/HPF. 
Microvascular proliferation:
Microvascular proliferation is formation of multilayered blood vessels 
from existing capillaries. It plays a large role in tumour growth and spread 
and is an indicator of a high malignancy grade glioma.
Leon et al  have shown that density of microvessels is a prognostic 
factor  of  astroglial  tumours29.  In  our  study  endothelial  proliferation  was 
noted only in glioblastoma multiforme (fig.16).  It  was seen in all  the 26 
cases of glioblastoma. Although in our study endothelial proliferation was 
noted only in high grade gliomas, it has been mentioned in literature32 that 
rarely endothelial proliferation can be seen in pilocytic astrocytoma (WHO 
Grade 1).
Giant cells:
      The presence of giant cells in histology is a feature of a high grade 
neoplasm mostly.  This  was  observed  in  our  study  wherein  all  14  cases 
(100%) of glioblastoma showed giant cells (fig.16) and were associated with 
features of endothelial proliferation and necrosis.
      According to Jellinger the frequent occurrence of giant cells as well as 
regressive  changes  with  necrosis  and  vascular  responses  are  indirect 
indicators  of  malignancy  which  coincide  with  histochemical  and 
biochemical data.23Schmidt and Urban et al in their study showed that giant 
cells in glioblastoma multiforme indicate a better prognosis. 
Necrosis:
     Necrosis is a distinguishing indicator of glioblastoma multiforme. It is 
incompatible with a diagnosis of anaplastic astrocytoma,though it may be 
present in anaplastic oligodendrogliomas and oligoastrocytomas.32 Necrosis 
is a sign of bad prognosis. The pattern of necrosis may be either geographic 
or palisading type.
      Necrosis as a feature of high grade malignancy has to be evaluated 
with great care as we have seen in our study that one case with necrosis 
proved to be a low grade glioma.  Most  often necrosis  is  associated with 
grade  IV  glioma  (fig.14)  as  the  percentage  of  high  grade  gliomas  with 
necrosis in our study was 95.65%.
Calcification:
     The  presence  of  calcification  in  9  out  of  110  cases  of  gliomas 
represents  an  incidence  of  8.18%.  Calcification  was  seen  in  66.66%  of 
oligodendrogliomas, 4.76% of low grade gliomas and 11.5% of high grade 
gliomas.  In low grade gliomas the incidence of calcification tended to be 
higher in young males.
   Tanaka Y et al found that only in astrocytomas both the duration of 
symptoms and the post operative survival time of the calcified cases were 
longer  than  those  of  the  uncalcified.  In  conclusion  that  it  is  not  the 
histological  type  but  duration  of  the  clinical  course  that  plays  a  more 
important role in calcification of gliomas.49   
       
 
SUMMARY
The present study included 110 cases of gliomas resected during the 
period from. May 2005 to August 2007. 
The salient features observed in this study are:
1. The most frequent glioma was Grade II astrocytoma seen in 45 cases 
(41%)
         followed by Grade IV astrocytoma seen in 26 cases (24%). 
2. The age group affected ranges from 4 months old infant to
      75 years with a mean age of 38 years.
3. Of 110 cases  in the study,  males  constituted 73 cases  (66.36%) and 
females 37 cases (33.63%).
4. The peak incidence was in the third decade with 27 cases constituting 
24.54% of the total number of cases.
5. The most common site in the present study was the temporal lobes with 
44 cases, followed by the frontal lobes with 25 cases.
6. Infratentorial gliomas which are considered rare tumours accounted for 
9% of the cases.
7. The most common presenting symptoms were headache associated with 
nausea  and  vomiting.  Recent  onset  seizures  were  the  next  most 
common symptom.
8. Non enhancing gliomas were malignant in 6 out of 38 cases of high 
grade  astrocytomas  (15.78%)  especially  in  older  patients.  Therefore 
histologic  confirmation  of  the  diagnosis  is  important  in  all  patients 
suspected of harboring a primary glial neoplasm.
9. WHO  grade  II  gliomas  formed  the  overwhelming  majority  with  55 
cases  forming  50% of  total.  Grade  I  gliomas  numbered  17 forming 
15.46% while grade III  and grade IV constituted 10.9% and 23.63% 
respectively.
10.Most of the grade II astrocytomas were diffuse astrocytomas forming 
45 out of 55 cases (40.9%). 
11.One  of  our  case  was  a  rare  variant  of  grade  II  glioma  namely 
pleomorphic xanthoastrocytoma (n=1).
                                          CONCLUSION
From our study we observe that non – enhancement of gliomas does 
not  equate  with low – grade malignancy.  This  fact  should  be taken into 
account  when  biopsy  and  treatment  are  being  planned  in  patients  with 
nonenhancing brain tumors.  
The  diagnosis  of  gliomas  has  always  depended  upon  conventional 
histo-morphological  study of  H & E stained sections.  The  prognosis  and 
response to treatment of the various types of gliomas correlates well with the 
present  WHO  grading  system.  Ancillary  techniques  like 
immunohistochemistry  and  electron  microscopy  are  usually  not  required 
unless the tumor is very undifferentiated and anaplastic.
A lot of research is being done with reference to gliomas and a whole 
host  of  new molecular  targets  like  bcl–2 etc  have  been  discovered.  The 
future holds promise that gliomas may be treated by non invasive methods 
like targeted molecular therapy.
 Although  current  emphasis  is  more  on  molecular,  genetic  and 
immunohistochemical  research,  the  principal  reliable  morphologic 
prognostic criterion – histologic grade of malignancy – still remains and is 
applied in clinical practice.   
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